论文部分内容阅读
目的探讨核苷酸切除修复交叉互补（ＥＲＣＣ）基因表达与肿瘤细胞对氯乙基亚硝脲（ＣＥＮＵ）耐药的关系。方法采用我们已建立的逆转录．聚合酶连锁反应（ＲＴ－ＰＣＲ）定量分析方法，对９株人胶质瘤细胞的ＥＲＣＣ－２基因表达进行测定，并与ＣＥＮＵ细胞毒性试验进行相关分析。结果ＥＲＣＣ－２基因表达与二氯乙基亚硝脲（ＢＣＮＵ）及二氯乙基肉芥子亚硝脲（ＳａｒＣＮＵ）耐药性之间有显著的正相关（ｒ＝０．６７２，Ｐ＝０．０４７和ｒ＝０．７２６，Ｐ＝０．０２８）。结论本研究提示ＥＲＣＣ－２基因表达在胶质瘤对亚硝脲类抗癌药耐药中起重要作用。
Objective To investigate the relationship between the nucleotide excision repair cross-complementarity (ERCC) gene expression and tumor cell resistance to chloroethyl nitrosourea (CENU). The method uses the reverse transcription we have established. Polymerase chain reaction (RT-PCR) quantitative analysis of 9 human glioma cells ERCC-2 gene expression was determined and CENU cytotoxicity test were analyzed. Results There was a significant positive correlation between ERCC-2 gene expression and drug resistance of BCNU and SarCNU (r = 0.672, P = 0 .047 and r = 0.726, P = 0.028). Conclusion This study suggests that ERCC-2 gene expression plays an important role in the resistance of glioma to nitrosourea anticancer drugs.